cagrilintide + semaglutide Blend Coadministered Cagrilintide and Semaglutide in

For the first time ever, our clinical records will officially acknowledge that Type 2 diabetes can be driven into remission

Leptin analogs and MC4R agonists are novel therapies that target genetic or hormonal causes of obesity

The world's biggest food company is targeting Ozempic users with small, protein-packed meals for under $5.

Physiological Effects Semaglutide exerts its therapeutic benefits through multiple complementary mechanisms: Enhanced Insulin Secretion: Stimulates glucose-dependent insulin release from pancreatic beta cells, improving postprandial glucose control[3][4] Glucagon Suppression: Inhibits glucagon release, reducing hepatic glucose production and improving fasting blood glucose levels[3][4] Delayed Gastric Emptying: Slows the movement of food from the stomach to the small intestine, reducing postprandial glucose excursions and promoting satiety[4][5] Appetite Reduction: Directly affects the central nervous system to decrease food intake and energy consumption[4][5] Improved Metabolic Flexibility: Enhances the body's ability to switch between energy substrates based on availability[2] At the cellular level, semaglutide primarily operates through the AMPK (AMP-activated protein kinase) pathway, which regulates cellular energy homeostasis and improves insulin sensitivity

Ozempic Butt describes loss of subcutaneous fat in the buttocks region during GLP-1 receptor agonist therapy

CVS Caremark covers Wegovy for 18% of commercial plans in 2026